Press Releases and Events

PRESS RELEASES

Press Release | April 11, 2024

Crinetics Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | March 19, 2024

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

READ MORE
Press Release | March 12, 2024

Crinetics Announces Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

READ MORE
Press Release | March 11, 2024

Crinetics Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | February 28, 2024

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

READ MORE
Press Release | February 28, 2024

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

READ MORE
Press Release | February 12, 2024

Crinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 10, 2024

Crinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 3, 2024

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

READ MORE
Press Release | December 18, 2023

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

READ MORE
9 / 25